Quick Search

PHDS HEALTHCARE RESEARCH Co., Ltd. (CRO) is a CRO company serving the world, a national high-tech enterprise, and one of the leading contract research institutions (Contract Research Organization) in the industry.

搜索历史清除全部记录
最多显示8条历史搜索记录噢~
All
  • All
  • Product Management
  • News

The Sino-American joint venture Dr.K-PHDS has been officially established.


Release time:

2007-07-04

On July 26, 2007, PHDS officially signed an agreement with the powerful Irvine Pharmaceutical Services, Inc. (IPS) in Beijing.

The Sino-American joint venture Dr.K-PHDS has been officially established.

On July 26, 2007, PHDS officially signed an agreement with the powerful American Irvine Pharmaceutical Services, Inc. (IPS) in Beijing. The legal representatives of both parties signed the cooperation agreement, officially establishing the Sino-American joint venture: Dr.K-PHDS. This is an unprecedented bridge linking Eastern and Western pharmaceutical endeavors, aimed at providing high-end services for global drug research and development with a comprehensive service system in the field of drug development.
IPS is a contract analytical testing laboratory in the United States that fully complies with cGMP requirements. IPS provides professional analytical chemistry and microbiology testing services for pharmaceutical, biotechnology, and medical device companies. The main areas of expertise include routine quality control final inspections, analytical support services during research and development (method development and validation, drug storage stability testing), and microbiology services.

PHDS is a global CRO company with outstanding expert consultants and an excellent CRA team, rich in clinical research experience and with numerous successful cases.

The newly established multinational joint venture Dr.K-PHDS, formed by the collaboration of two strong entities, primarily focuses on undertaking international multicenter clinical research and clinical studies for new and imported drugs. Coupled with IPS's pharmaceutical pharmacological analysis capabilities, it has created a comprehensive drug research and development service system. The strong human resources, social resources, and unique advantages of multinational alliances are the core competitiveness of Dr.K-PHDS.

Keyword:

Relevant regulations and policies


Key points and judgment principles for the quality management of non-clinical research of drugs

In order to standardize the on-site inspection work of Good Laboratory Practice (GLP) for non-clinical drug research and improve inspection quality, the "Key Points and Determination Principles for the Inspection of Good Laboratory Practice in Non-Clinical Drug Research" has been formulated in accordance with relevant requirements such as the "Drug Administration Law of the People's Republic of China," "Good Laboratory Practice for Non-Clinical Drug Research," and "Management Measures for the Certification of Good Laboratory Practice for Non-Clinical Drug Research."

2024-11-22

Technical requirements for the latest declaration data electronic disc

In order to further improve the quality and efficiency of the preparation of electronic application materials for drug registration, and to standardize the management of electronic application materials, our center has updated the "Technical Requirements for Electronic Discs of Application Materials" and "Structure of Electronic Documents for Drug Registration Applications" published on December 2, 2022, based on feedback.

2024-11-22

PHDS was elected as: Vice President unit of the China Food and Drug Enterprise Quality Safety Promotion Association

In December 2023, PHDS HEALTHCARE RESEARCH Co., Ltd. was elected as the vice president unit of the China Food and Drug Enterprise Quality Safety Promotion Association, as well as the vice chairman of its subordinate digital professional committee (Certificate No.: Zhong Shi Yao An Cu Hui Zheng Zi 798). The election and award ceremony took place at the Three Gorges Hospital of Chongqing Medical University.

2024-11-22

The Wuxi Global Oral Forum and the High-Quality Development Conference of the China Food and Drug Promotion Association -- Bo Shi Zhi Xing was elected as an executive council unit and an excellent member unit.

On March 26-27, 2024, the China Wuxi Global Oral Forum and the China Food and Drug Promotion Association High-Quality Development Conference, guided by the Wuxi Municipal People's Government and the Wuxi Council for the Promotion of International Trade, and organized by the China Food and Drug Promotion Association and the Oral Health Committee of the China Food and Drug Promotion Association, will be grandly held at the Wuxi International Conference Center.

2024-11-22